Anti-endothelin drugs in solid tumors

Expert Opinion on Emerging Drugs

Volumn 15, Issue 1, 2010, Pages 27-40

  Russo, Antonio ^a   Bronte, Giuseppe ^a   Rizzo, Sergio ^a   Fanale, Daniele ^a   Di Gaudio, Francesca ^a   Gebbia, Nicola ^a   Bazan, Viviana ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Atrasentan; Endothelins; Prostate cancer; Zibotentan

Indexed keywords

ATRASENTAN; BOSENTAN; ENDOTHELIN; ENDOTHELIN RECEPTOR; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; PLACEBO; UNCLASSIFIED DRUG; ZIBOTENTAN;

ANTINEOPLASTIC ACTIVITY; BACKACHE; BONE METASTASIS; CANCER CONTROL; CANCER GROWTH; CANCER PAIN; CANCER SURVIVAL; CLINICAL TRIAL; FATIGUE; HEADACHE; HUMAN; LIVER DYSFUNCTION; MELANOMA; NAUSEA; NOSE CONGESTION; OVERALL SURVIVAL; PERIPHERAL EDEMA; PROSTATE CANCER; REVIEW; RHINITIS; SOLID TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DELIVERY SYSTEMS; DRUGS, INVESTIGATIONAL; ENDOTHELINS; HUMANS; MALE; MODELS, BIOLOGICAL; NEOPLASMS; PROSTATIC NEOPLASMS; PYRROLIDINES; RECEPTORS, ENDOTHELIN; SIGNAL TRANSDUCTION;

EID: 77749261162     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210903571667     Document Type: Review

References (83)

1. Yanagisawa M, Inoue A, Ishikawa T, et al. Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proc Natl Acad Sci USA 1988;85(18):6964-7
2. Masaki T. Historical review: endothelin. Trends Pharmacol Sci 2004;25(4):219-24
3. Bagnato A, Natali PG. Endothelin receptors as novel targets in tumor therapy. J Transl Med 2004;2(1):16
4. Levin ER. Endothelins. N Engl J Med 1995;333(6):356-63
5. Masaki T. The endothelin family: an overview. J Cardiovasc Pharmacol 2000;35(4 Suppl 2):S3-5
6. Schweizer A, Valdenaire O, Nelbock P, et al. Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations. Biochem J 1997;328 (Pt 3):871-7
7. Xu D, Emoto N, Giaid A, et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994;78(3):473-85
8. Rubin SA, Levin ER. Clinical review 53: The endocrinology of vasoactive peptides: synthesis to function. J Clin Endocrinol Metab 1994;78(1):6-10
9. Clozel M, Fischli W, Guilly C. Specific binding of endothelin on human vascular smooth muscle cells in culture. J Clin Invest 1989;83(5):1758-61
10. Clozel M, Gray GA, Breu V, et al. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun 1992;186(2):867-73
11. Haynes WG, Webb DJ. The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci (Lond) 1993;84(5):485-500
12. Foster N, Loi TH, Owe-Young R, Stanley KK. Lysosomal traffic of liganded endothelin B receptor. Biochim Biophys Acta 2003;1642(1-2):45-52
13. Bkaily G, Nader M, Avedanian L, et al. G-protein-coupled receptors, channels, and Na+-H+ exchanger in nuclear membranes of heart, hepatic, vascular endothelial, and smooth muscle cells. Can J Physiol Pharmacol 2006;84(3-4):431-41
14. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3(2):110-6
15. Remuzzi G, Perico N, Benigni A. New therapeutics that antagonize endothelin: promises and frustrations. Nat Rev Drug Discov 2002;1(12):986-1001
16. Ali H, Dashwood M, Dawas K, et al. Endothelin receptor expression in colorectal cancer. J Cardiovasc Pharmacol 2000 36(5 Suppl 1):S69-71
17. Hirata Y. Endothelin-1 receptors in cultured vascular smooth muscle cells and cardiocytes of rats. J Cardiovasc Pharmacol 1989;13(Suppl 5):S157-8
18. Kusuhara M, Yamaguchi K, Ohnishi A, et al. Endothelin potentiates growth factor-stimulated DNA synthesis in Swiss 3T3 cells. Jpn J Cancer Res 1989;80(4):302-5
19. Shichiri M, Hirata Y, Marumo F. Endothelin-1 as an autocrine/paracrine factor for human tumor cell lines. J Cardiovasc Pharmacol 1991;17(Suppl 7):S76-8
20. Simonson MS, Wann S, Mene P, et al. Endothelin-1 activates the phosphoinositide cascade in cultured glomerular mesangial cells. J Cardiovasc Pharmacol 1989;13(Suppl 5):S80-3, discussion S4
21. Bagnato A, Spinella F, Rosano L. Emerging role of the endothelin axis in ovarian tumor progression. Endocr Relat Cancer 2005;12(4):761-72
22. Rauh A, Windischhofer W, Kovacevic A, et al. Endothelin (ET)-1 and ET-3 promote expression of c-fos and c-jun in human choriocarcinoma via ET(B) receptor-mediated G(i)- and G (q)-pathways and MAP kinase activation. Br J Pharmacol 2008;154(1):13-24
23. Bagnato A, Catt KJ. Endothelins as autocrine regulators of tumor cell growth. Trends Endocrinol Metab 1998;9(9):378-83
24. Bagnato A, Tecce R, Di Castro V, Catt KJ. Activation of mitogenic signaling by endothelin 1 in ovarian carcinoma cells. Cancer Res 1997;57(7):1306-11
25. Vacca F, Bagnato A, Catt KJ, Tecce R. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res 2000;60(18):5310-7
26. Eguchi S, Hirata Y, Imai T, et al. Phenotypic change of endothelin receptor subtype in cultured rat vascular smooth muscle cells. Endocrinology 1994;134(1):222-8
27. Battistini B, Chailler P, D'Orleans-Juste P, et al. Growth regulatory properties of endothelins. Peptides 1993;14(2):385-99
28. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407(6801):249-57
29. Salani D, Taraboletti G, Rosano L, et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 2000;157(5):1703-11
30. Bagnato A, Cirilli A, Salani D, et al. Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res 2002;62(22):6381-4
31. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4(6):431-6
32. Denkert C, Kobel M, Pest S, et al. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 2002;160(3):893-903
33. Ferrandina G, Lauriola L, Zannoni GF, et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 2002;13(8):1205-11
34. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388(6638):190-5
35. Egidy G, Eberl LP, Valdenaire O, et al. The endothelin system in human glioblastoma. Lab Invest 2000;80(11):1681-9
36. Peduto Eberl L, Bovey R, Juillerat-Jeanneret L. Endothelin-receptor antagonists are proapoptotic and antiproliferative in human colon cancer cells. Br J Cancer 2003;88(5):788-95
37. Okazawa M, Shiraki T, Ninomiya H, et al. Endothelin-induced apoptosis of A375 human melanoma cells. J Biol Chem 1998;273(20):12584-92
38. Salani D, Di Castro V, Nicotra MR, et al. Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol 2000;157(5):1537-47
39. Spinella F, Rosano L, Di Castro V, et al. Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem 2004;279(45):46700-5
40. Spinella F, Rosano L, Di Castro V, et al. Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells. J Biol Chem 2003;278(42):41294-301
41. Rosano L, Spinella F, Di Castro V, et al. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res 2005;65(24):11649-57
42. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1(9):944-9
43. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006;12(20 Pt 2):6296s-300s
44. Nelson JB, Nguyen SH, Wu-Wong JR, et al. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 1999;53(5):1063-9
45. Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer 2003;97(Suppl 3):779-84
46. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003;100(19):10954-9
47. Corder R, Douthwaite JA, Lees DM, et al. Endothelin-1 synthesis reduced by red wine. Nature 2001;414(6866):863-4
48. Spinella F, Rosano L, Di Castro V, et al. Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. Mol Cancer Ther 2006;5(6):1483-92
49. Jeng AY, Mulder P, Kwan AL, Battistini B. Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications. Can J Physiol Pharmacol 2002;80(5):440-9
50. Kajiyama H, Shibata K, Terauchi M, et al. Neutral endopeptidase 24.11/CD10 suppresses progressive potential in ovarian carcinoma in vitro and in vivo. Clin Cancer Res 2005;11(5):1798-808
51. Rosano L, Spinella F, Salani D, et al. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res 2003;63(10):2447-53
52. Jazaeri AA, Awtrey CS, Chandramouli GV, et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 2005;11(17):6300-10
53. Smollich M, Wulfing P. The endothelin axis: a novel target for pharmacotherapy of female malignancies. Curr Vasc Pharmacol 2007;5(3):239-48
54. Venuti A, Salani D, Manni V, et al. Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy. FASEB J 2000;14(14):2277-83
55. Mai HQ, Zeng ZY, Zhang CQ, et al. Elevated plasma big ET-1 is associated with distant failure in patients with advanced-stage nasopharyngeal carcinoma. Cancer 2006;106(7):1548-53
56. Mai HQ, Zeng ZY, Feng KT, et al. Therapeutic targeting of the endothelin a receptor in human nasopharyngeal carcinoma. Cancer Sci 2006;97(12):1388-95
57. Titus B, Frierson HF Jr, Conaway M, et al. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 2005;65(16):7320-7
58. Rosano L, Di Castro V, Spinella F, et al. ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation. Exp Biol Med (Maywood) 2006;231(6):1132-5
59. Rosano L, Di Castro V, Spinella F, et al. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther 2007;6(7):2003-11
60. Rosano L, Di Castro V, Spinella F, et al. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res 2007;67(13):6351-9
61. Berger Y, Bernasconi CC, Juillerat-Jeanneret L. Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents. Exp Biol Med (Maywood) 2006;231(6):1111-9
62. Bagnato A, Rosano L, Di Castro V, et al. Endothelin receptor blockade inhibits proliferation of Kaposi's sarcoma cells. Am J Pathol 2001;158(3):841-7
63. Rosano L, Spinella F, Di Castro V, et al. Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo. Am J Pathol 2003;163(2):753-62
64. Lahav R, Heffner G, Patterson PH. An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci USA 1999;96(20):11496-500
65. Spinella F, Rosano L, Di Castro V, et al. Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells. Cancer Res 2007;67(4):1725-34
66. Samara E, Dutta S, Cao G, et al. Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist. J Clin Pharmacol 2001;41(4):397-403
67. Morris CD, Rose A, Curwen J, et al. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer 2005;92(12):2148-52
68. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21(4):679-89
69. Zonnenberg BA, Groenewegen G, Janus TJ, et al. Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. Clin Cancer Res 2003;9(8):2965-72
70. Ferreira SH, Romitelli M, de Nucci G. Endothelin-1 participation in overt and inflammatory pain. J Cardiovasc Pharmacol 1989;13(Suppl 5):S220-2
71. Raffa RB, Schupsky JJ, Martinez RP, Jacoby HI. Endothelin-1-induced nociception. Life Sci 1991;49(11):PL61-5
72. Khodorova A, Navarro B, Jouaville LS, et al. Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury. Nat Med 2003;9(8):1055-61
73. Nelson JB. Endothelin receptor antagonists. World J Urol 2005;23(1):19-27
74. Nelson JB, Nabulsi AA, Vogelzang NJ, et al. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 2003;169(3):1143-9
75. Takuwa Y, Ohue Y, Takuwa N, Yamashita K. Endothelin-1 activates phospholipase C and mobilizes Ca2+ from extra- and intracellular pools in osteoblastic cells. Am J Physiol 1989;257(6 Pt 1):E797-803
76. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007;110(9):1959-66
77. Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008;113(9):2478-87
78. Michaelson MD, Kaufman DS, Kantoff P, et al. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer 2006;107(3):530-5
79. Armstrong AJ, Creel P, Turnbull J, et al. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2008;14(19):6270-6
80. Chiappori AA, Haura E, Rodriguez FA, et al. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res 2008;14(5):1464-9
81. James ND, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009;55(5):1112-23
82. Schelman WR, Liu G, Wilding G, et al. A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Invest New Drugs 2009, doi: 10.1007/s10637-009-9318-5
83. Kefford R, Beith JM, Van Hazel GA, et al. A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs 2007;25(3):247-52